骨性关节炎治疗药物:开发平台评估与到2018年为止的市场预测 是由出版商GlobalData在2011年11月所出版的。
这份英文市场调查报告书包含Pages: 80 价格从美金3500起跳。
本报告提供骨性关节炎(Osteoarthritis)治疗法研究及开发的最新趋势调查，进行相关的市场预测，疾病概要及处置法，汇整全球及主要7个国家的市场规模测量与预测(2005-2010年2018年)，竞争结构、临床实验进行状况相关的开发平台评估，今后的市场趋势及企业策略相关的策略性考察等等信息，为您概述为以下内容。
第1章 目录
第2章 简介
- 概要
- 免疫学
- 病因·病情
- 风险要素
- 徵兆
- 骨性关节炎的诊断
- 治疗
- 该报告内容架构
第3章 市场特徵
- 市场规模测量:主要7个国家（2005-2010年)
- 市场规模预测:主要7个国家（2010-2018年)
- 市场规模测量:美国(2005-2010年)
- 市场规模预测:美国(2010-2018年)
- 市场规模测量:英国(2005-2010年)
- 市场规模预测:英国(2010-2018年)
- 市场规模测量:法国(2005-2010年)
- 市场规模预测:法国(2010-2018年)
- 市场规模测量:德国(2005-2010年)
- 市场规模预测:德国(2010-2018年)
- 市场规模测量:义大利(2005-2010年)
- 市场规模预测:义大利(2010-2018年)
- 市场规模测量:西班牙(2005-2010年)
- 市场规模预测:西班牙(2010-2018年)
- 市场规模测量:日本(2005-2010年)
- 市场规模预测:日本(2010-2018年)
- 市场促进·阻碍因素
- 影响未来市场的今后主要事件
- 机会及未饱和需求
- 主要的结论
第4章 竞争分析
- 概要
- 一般地被利用的产品简介
- sereburekkusu(serekokishibu)
- shinbaruta(duloxetine hydrochloride)
- hiarugan(玻尿酸钠)
- Nucynta (tapentadol)
- borutarengeru(jikurofenakunatoriumu局部凝胶1％)
- 主要的结论
第5章 开发平台评估
- 概要
- 策略性开发平台评估
- 登记前的分子
- 阶段III开发平台
- 阶段II/III开发平台
- 阶段II开发平台
- 阶段I/II开发平台
- 阶段I开发平台
- 前临床开发平台
- 药物发明开发平台
- 各行动机制开发平台
- 技术趋势分析架构
- 临床实验阶段的潜力药物
- 有潜力的药剂的分子简介
- Cartistem
- Civanex (civamide, zucapsaicin)
- Strontium Chloride Hexahydrate (2PX)
- Oral Salmon Calcitonin (SMC021)
- BEMA Buprenorphine
- IP 880及IP 889
- 主要的结论
第6章 临床实验蓝图
- 各地区·各国的临床实验数(美国·EU5个国家·日本)
- 各阶段临床实验数
- 各筛检阶段临床实验数
- 有潜力的赞助商
- 参加骨性关节炎临床实验的前几名企业
第7章 策略性评估
第8章 今后的市场参加企业
- 简介
- BioDelivery Sciences International
- Cephalon, Inc.
- Iroko Pharmaceuticals, LLC
- Novartis AG
- SantoSolve AS
- Winston Pharmaceuticals, Inc.
- 其他的企业
第9章 专利·合作交易
第10章 附录
图表一览
Abstract
Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and driving the global osteoarthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global OA therapeutics market was worth $4.4 billion in 2010 and forecasts it to grow at a compound annual growth rate (CAGR) of 3.8% to reach $5.9 billion by 2018. The current treatment options for OA offer only symptomatic relief and are primarily dominated by generics. There are no disease modifying osteoarthritis drugs (DMOAD) currently approved in the OA therapeutics market and the late stage pipeline also lacks DMOADs except SMC021. Owing to all the above factors the OA therapeutics market is expected to show slow growth till 2018.
Scope
The report provides information on the key drivers and challenges of the osteoarthritis therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) osteoarthritis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing analysis of the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for osteoarthritis fall under major therapeutic classes such as stem cell therapy, cyclooxygenase (COX) inhibitor, cathepsin inhibitors, opioid receptor agonist, anti-nerve growth factor (NGF) inhibitor, transient receptor potential vanilloid-1 (TRPV-1) antagonists, cyclooxygenase inhibiting nitric oxide donor, phosphodiesterase inhibitor and calcitonin receptor agonist.
- Analysis of current and future competition in the global osteoarthritis market is provided. Key market players covered are BioDelivery Sciences International, Cephalon Inc, Iroko Pharmaceuticals, LLC, Novartis AG, SantoSolve AS and Winston Pharmaceuticals, Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoarthritis therapeutics market.
- Analysis of key recent licensing and partnership agreements in osteoarthritis therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global osteoarthritis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoarthritis therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global osteoarthritis therapeutics market landscape? - Identify, understand and capitalize.
TOC
1 Table of contents
1 Table of contents 3
- 1.1 List of Tables 5
- 1.2 List of Figures 6
2 Osteoarthritis Therapeutics - Introduction 7
- 2.1 Overview 7
- 2.2 Epidemiology 7
- 2.3 Etiology and Pathophysiology 8
- 2.4 Risk Factors 9
- 2.5 Symptoms 10
- 2.6 Diagnosis of OA 10
2.6.1 Clinical History 10
- 2.6.2 Physical Examination 10
- 2.6.3 Diagnostic Imaging Techniques 11
- 2.7 Treatment 11
- 2.7.1 Non-Pharmacological Therapy 12
- 2.7.2 Pharmacological Therapy 12
- 2.7.3 Surgical Treatment 13
- 2.8 GlobalData Pipeline Report Guidance 14
3 Osteoarthritis Therapeutics - Market Characterization 15
- 3.1 Major Markets, Market Size (2005-2010) 15
- 3.2 Major Markets, Market Forecast (2010-2018) 17
- 3.3 OA Therapeutics Market Size (2005-2010) - The US 19
- 3.4 OA Therapeutics Market Forecast (2010-2018) - The US 20
- 3.5 OA Therapeutics Market Size (2005-2010) - The UK 21
- 3.6 OA Therapeutics Market Forecast (2010-2018) - The UK 22
- 3.7 OA Therapeutics Market Size (2005-2010) - France 23
- 3.8 OA Therapeutics Market Forecast (2010-2018) - France 24
- 3.9 OA Therapeutics Market Size (2005-2010) - Germany 25
- 3.10 OA Therapeutics Market Forecast (2010-2018) - Germany 26
- 3.11 OA Therapeutics Market Size (2005-2010) - Italy 27
- 3.12 OA Therapeutics Market Forecast (2010-2018) - Italy 28
- 3.13 OA Therapeutics Market Size (2005-2010) - Spain 29
- 3.14 OA Therapeutics Market Forecast (2010-2018) - Spain 30
- 3.15 OA Therapeutics Market Size (2005-2010) - Japan 31
- 3.16 OA Therapeutics Market Forecast (2010-2018) - Japan 32
- 3.17 Drivers and Barriers for the OA Therapeutics Market 33
- 3.17.1 Drivers for the OA Therapeutics Market 33
- 3.17.2 Barriers for the OA Therapeutics Market 33
- 3.18 Key Events Impacting the Future Market 34
- 3.19 Opportunity and Unmet Need 35
- 3.20 Key Takeaway 35
4 OA Therapeutics Market - Competitive Assessment 36
- 4.1 Overview 36
- 4.1.1 Strategic Competitor Assessment 36
- 4.2 Profiles of Commonly Used Products in the OA Therapeutics Market 37
- 4.2.1 5.2.1 Celebrex (celecoxib) 37
- 4.2.2 Cymbalta (duloxetine hydrochloride) 37
- 4.2.3 Hyalgan (sodium hyaluronate) 38
- 4.2.4 Nucynta (tapentadol) 39
- 4.2.5 Voltaren Gel (diclofenac sodium topical gel 1%) 40
- 4.3 Key Takeaway 40
5 OA Therapeutics Market - Pipeline Assessment 41
- 5.1 Overview 41
- 5.2 Strategic Pipeline Assessment 41
- 5.2.1 OA Therapeutics - Molecules in Pre-Registration 43
- 5.2.2 OA Therapeutics - Phase III Pipeline 43
- 5.2.3 OA Therapeutics - Phase II/III Pipeline 43
- 5.2.4 OA Therapeutics - Phase II Pipeline 43
- 5.2.5 OA Therapeutics - Phase I/II Pipeline 44
- 5.2.6 OA Therapeutics - Phase I Pipeline 44
- 5.2.7 OA Therapeutics - Preclinical Pipeline 45
- 5.2.8 OA Therapeutics - Discovery Pipeline 45
- 5.3 OA Pipeline by Mechanism of Action 46
- 5.4 OA Technology Trends Analytical Framework 48
- 5.5 OA Therapeutics - Promising Drugs under Clinical Development 49
- 5.6 Molecule Profile for Promising Drugs under Clinical Development 50
- 5.6.1 Cartistem 50
- 5.6.2 Civanex (civamide, zucapsaicin) 50
- 5.6.3 Strontium Chloride Hexahydrate (2PX) 51
- 5.6.4 Oral Salmon Calcitonin (SMC021) 51
- 5.6.5 BEMA Buprenorphine 52
- 5.6.6 IP 880 and IP 889 52
- 5.7 Key Takeaway 52
6 Osteoarthritis Therapeutics - Clinical Trials Mapping 53
- 6.1 Clinical Trials by Country (US, EU5 and Japan) 53
- 6.2 Clinical Trials by Phase 54
- 6.3 Clinical Trials by Trial Status 55
- 6.4 Prominent Sponsors 56
- 6.5 Top Companies Participating in OA Therapeutics Clinical Trials 58
7 Osteoarthritis Therapeutics - Strategic Assessment 59
- 7.1 Osteoarthritis Therapeutics - Implications for Future Market Competition 59
8 Osteoarthritis Therapeutics - Future Players in the Market 60
- 8.1 Introduction 60
- 8.1.1 BioDelivery Sciences International 60
- 8.1.2 Cephalon, Inc. 61
- 8.1.3 Iroko Pharmaceuticals, LLC 63
- 8.1.4 Novartis AG 64
- 8.1.5 SantoSolve AS 66
- 8.1.6 Winston Pharmaceuticals, Inc. 66
- 8.1.7 Other Companies in Osteoarthritis Therapeutics Market 67
9 OA Therapeutics - Licensing and Partnership Deals 69
10 Osteoarthritis Therapeutics - Appendix 73
- 10.1 Definitions 73
- 10.2 Acronyms 73
- 10.3 Research Methodology 74
- 10.3.1 Coverage 74
- 10.3.2 Secondary Research 75
- 10.3.3 Forecasting 75
- 10.3.4 Primary Research 78
- 10.3.5 Expert Panel Validation 78
- 10.4 Contact Us 78
- 10.5 Disclaimer 78
- 10.6 Bibliography 79
List of Tables
1.1 List of Tables
- Table 1: Osteoarthritis - Prevalence, Major Markets, 2010 7
- Table 2: Surgical Procedures for Osteoarthritis 13
- Table 3: OA Therapeutics Market, Major Markets, Revenue ($bn), 2005 - 2010 15
- Table 4: OA Therapeutics Market, Major Markets, Forecast ($bn), 2010 - 2018 17
- Table 5: OA Therapeutics Market, The US, Revenue ($bn), 2005 - 2010 19
- Table 6: OA Therapeutics Market, The US, Forecast ($bn), 2010 - 2018 20
- Table 7: OA Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 21
- Table 8: OA Therapeutics Market, The UK, Forecast ($m), 2010 - 2018 22
- Table 9: OA Therapeutics Market, France, Revenue ($m), 2005 - 2010 23
- Table 10: OA Therapeutics Market, France, Forecast ($m), 2010 - 2018 24
- Table 11: OA Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 25
- Table 12: OA Therapeutics Market, Germany, Forecast ($m), 2010 - 2018 26
- Table 13: OA Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 27
- Table 14: OA Therapeutics Market, Italy, Forecast ($m), 2010 - 2018 28
- Table 15: OA Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 29
- Table 16: OA Therapeutics Market, Spain, Forecast ($m), 2010 - 2018 30
- Table 17: OA Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 31
- Table 18: OA Therapeutics Market, Japan, Forecast ($m), 2010 - 2018 32
- Table 19: OA Therapeutics - Molecules in Pre-Registration 43
- Table 20: OA Therapeutics - Phase III Pipeline 43
- Table 21: OA Therapeutics - Phase II/III Pipeline 43
- Table 22: OA Therapeutics - Phase II Pipeline 43
- Table 23: OA Therapeutics - Phase I/II Pipeline 44
- Table 24: OA Therapeutics - Phase I Pipeline 44
- Table 25: OA Therapeutics - Preclinical Pipeline 45
- Table 26: OA Therapeutics - Discovery Pipeline 45
- Table 27: Other Mechanisms of Action from Figure 29 47
- Table 28: OA Therapeutics - Promising Drugs Under Clinical Development, 2011 49
- Table 29: OA Therapeutics - Clinical Trials by Country, 2011 53
- Table 30: OA Therapeutics - Clinical Trials by Phase, 2011 54
- Table 31: OA Therapeutics - Clinical Trials by Status, 2011 55
- Table 32: OA Therapeutics, Overall Sponsors, 2011 56
- Table 33: OA Therapeutics - Prominent Sponsors, 2011 57
- Table 34: OA Therapeutics - Top Companies Participating in Clinical Trials, 2011 58
- Table 35: BioDelivery Sciences International - Osteoarthritis Therapeutics Pipeline 61
- Table 36: Cephalon, Inc. - Osteoarthritis Therapeutics Pipeline 63
- Table 37: Iroko Pharmaceuticals, LLC - Osteoarthritis Therapeutics Pipeline 63
- Table 38: Novartis AG - Osteoarthritis Therapeutics Pipeline 65
- Table 39: SantoSolve AS - Osteoarthritis Therapeutics Pipeline 66
- Table 40: Winston Pharmaceuticals, Inc. - Osteoarthritis Therapeutics Pipeline 66
- Table 41: OA Therapeutics Market- Future Players 67
- Table 42: OA Therapeutics - Licensing and Partnership Deals 69
List of Figures
1.2 List of Figures
- Figure 1: Aetiology and Pathophysiology of Osteoarthritis 8
- Figure 2: Articular Structures Affected in Osteoarthritis 9
- Figure 3: OA Treatment Overview 11
- Figure 4: OA Therapeutics Market, Major Markets, Revenue ($bn), 2005 - 2010 15
- Figure 5: OA Therapeutics, Market Share ($m), 2010 16
- Figure 6: OA Therapeutics Market, Major Markets, Forecast ($bn), 2010 - 2018 17
- Figure 7: OA Therapeutics, Market Share ($m), 2018 18
- Figure 8: OA Therapeutics Market, The US, Revenue ($bn), 2005 - 2010 19
- Figure 9: OA Therapeutics Market, The US, Forecast ($bn), 2010 - 2018 20
- Figure 10: OA Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 21
- Figure 11: OA Therapeutics Market, The UK, Forecast ($m), 2010 - 2018 22
- Figure 12: OA Therapeutics Market, France, Revenue ($m), 2005 - 2010 23
- Figure 13: OA Therapeutics Market, France, Forecast ($m), 2010 - 2018 24
- Figure 14: OA Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 25
- Figure 15: OA Therapeutics Market, Germany, Forecast ($m), 2010 - 2018 26
- Figure 16: OA Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 27
- Figure 17: OA Therapeutics Market, Italy, Forecast ($m), 2010 - 2018 28
- Figure 18: OA Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 29
- Figure 19: OA Therapeutics Market, Spain, Forecast ($m), 2010 - 2018 30
- Figure 20: OA Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 31
- Figure 21: OA Therapeutics Market, Japan, Forecast ($m), 2010 - 2018 32
- Figure 22: OA Therapeutics Market, Drivers and Restraints 2011 34
- Figure 23: Opportunity and Unmet Need in the OA Therapeutics Market, 2011 35
- Figure 24: OA Therapeutics - Strategic Competitor Assessment, 2011 36
- Figure 25: OA Therapeutics - Pipeline by Phase of Clinical Development, 2011 42
- Figure 26: OA Therapeutics Pipeline - DMOAD versus Symptomatic Relief, 2011 42
- Figure 27: OA Market - Clinical Pipeline by Mechanism of Action, 2011 46
- Figure 28: Technology Trends Analytical Framework of the OA Pipeline, 2011 48
- Figure 29: Technology Trends Analytical Framework of the OA Pipeline - Description, 2011 49
- Figure 30: OA Therapeutics - Clinical Trials by Country, 2011 53
- Figure 31: OA Therapeutics - Clinical Trials by Phase, 2011 54
- Figure 32: OA Therapeutics - Clinical Trials by Status, 2011 55
- Figure 33: OA Therapeutics - Overall Sponsors, 2011 56
- Figure 34: OA Therapeutics - Prominent Sponsors, 2011 57
- Figure 35: OA Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 58
- Figure 36: Implications for Future Market Competition in the Osteoarthritis Therapeutics Market, 2011 59
- Figure 37: OA Therapeutics Market - Clinical Pipeline by Company , 2011 60
- Figure 38: GlobalData Market Forecasting Model 77
变形性关节症治疗药市场－疾病修饰性治疗药的缺乏成为阻碍市场成长的主要原因
2011年11月16日
Global Information, Inc.已开始销售GlobalData所发行的报告书「Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (骨性关节炎治疗药物:开发平台评估与到2018年为止的市场预测)」
变形性关节症(OA)在关节炎中亦是全世界最一般的类型，是造成身体障碍的主要原因。
再则，此疾病亦被称为变性关节病、肥厚性关节炎、退化性关节炎。
OA是慢性进行性的变性关节病，其特徵有关节软骨阶段性磨损、骨头肥大、软骨下骨硬化、以及在滑膜和关节包上一连串生物化学和形态的变化。
罹病关节上能看到肿、有热的感觉、吱嘎作响、硬化等症状，因会疼痛，有时行动变得困难。
OA是全部年龄的人都会发病的疾病，然一般以高龄及中年层最容易发病。
OA的发病率随年龄增高，此乃因筋骨格系发生变化。此外，女性比男性的发病频率高。
患病关节及疾病的严重度，与关节损伤和肥胖、影响遗传风险的要因和关节构造上的要因有关。
OA是在肩膀、肘、手腕关节、膝、腰及背脊骨的关节容易发病的疾病。
变形性关节症治疗药的全球市场缓慢成长
2010年OA治疗药市场为44亿美元，预测将以CAGR 3.8％扩大，2018年时达到59亿美元。
预测2018年美国市场亦持续增加全球最大的收益。
OA的治疗药没有疾病修饰药。
此外，不承认预防维持药，亦没有临床开发后期阶段的东西。
管道大部分都是减轻症状的治疗药，而非OA疾病进行中造成变化的疾病修饰药。
因有此要因，预测OA治疗药市场到2018年将稳健成长。
|
